Feratab

Quick links to important sections

Feratab

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feratab

Quick Facts

Property Description
Active ingredient Ferrous Sulfate
Form Oral tablet (often film-coated)
Pharmacological class Antianemic agent / Hematinic
Common purpose Iron Restoration
Origin Synthetic inorganic salt

What Type of Medicine is Feratab?

Feratab is the trade name for an oral tablet containing the active ingredient Ferrous Sulfate, which is fundamentally classified as an antianemic agent. This pharmaceutical preparation belongs to the larger group of iron replacement products or hematinics, primarily designed to address deficiencies in the body's iron supply. This compound supports the maintenance of systemic oxygen-carrying capacity. Feratab is commonly available over-the-counter (OTC), making it readily accessible for individuals requiring mineral supplementation. This medication is taken by the oral route and is defined as a single-ingredient product, containing only the active iron compound necessary for its therapeutic effect.

Composition and Origin of the Active Ingredient

The core component of the tablet is Ferrous Sulfate (iron(II) sulfate), which falls within the B-group of antianemia medicines. This ingredient is an inorganic, synthetic iron salt, and its significance lies in its ability to deliver elemental iron, which is the form the body utilizes directly. The formulation of Feratab often utilizes a specific film-coating, a feature intended to support digestive tolerance in iron supplementation. Unlike naturally occurring complex compounds, the product is a chemically defined substance precisely formulated within the oral tablet to ensure reliable and quantifiable delivery of the mineral.

General Purpose: Iron Restoration and Hemoglobin Support

The general purpose of Feratab is to facilitate iron restoration and support the necessary components for blood health. By supplying the crucial elemental iron, the medication enables the body to synthesize adequate quantities of hemoglobin, the protein in red blood cells that is essential for effective oxygen transport. A typical neutral use scenario includes supporting pregnant individuals who have higher iron requirements. This fundamental action ensures the body can maintain adequate iron stores, which is vital for numerous metabolic functions and overall systemic performance, including energy production and cell growth.

Regulatory References

  1. Ferrous Sulfate (Iron Supplement)
  2. FDA Ferrous Sulfate Drug Label

What side effects are possible with Feratab?

Possible Side Effects and Safety Information

Critical Safety Warning

Accidental overdose of iron-containing products, including Feratab (ferrous sulfate), is a leading cause of fatal poisoning in children under six years of age. Due to this severe risk, all iron products carry a mandatory, prominent regulatory warning. In the event of suspected accidental ingestion or overdose, emergency medical attention or immediate contact with a poison control center is necessary.

Adverse Reactions

The most common adverse reactions reported in regulatory documents are generally related to the gastrointestinal system and may be dose-related.

System-Organ Class Common Adverse Reactions
Gastrointestinal Constipation, diarrhea, nausea, abdominal pain, upset stomach, loss of appetite, stomach cramps.
Stool Color Stools may become dark, black, or tarry due to unabsorbed iron. This is a common and medically insignificant effect.

Serious Safety Events

Certain severe reactions require immediate medical evaluation, as documented in official regulatory sources:

  • Allergic Reactions: Signs of a severe allergic reaction (hypersensitivity), including rash, hives, difficulty breathing, tightness in the chest or throat, and swelling of the face, lips, tongue, or throat.
  • Gastrointestinal Toxicity: Vomiting blood or material that looks like coffee grounds, or passing bloody or tarry stools, which can indicate serious gastrointestinal irritation or bleeding.

Restrictions and Limitations

Official prescribing information notes that Feratab is generally contraindicated (should not be used) in patients with conditions that involve iron overload, such as hemochromatosis or hemosiderosis, and in those with anemias that are not caused by iron deficiency (e.g., hemolytic anemia, thalassemia). Safety considerations also include the potential for the product to cause or exacerbate gastrointestinal irritation, particularly in patients with a history of peptic ulcer disease or inflammatory bowel conditions.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Feratab (Ferrous Sulfate) overdose outlines a severe, potentially fatal, multistage toxicity that requires immediate medical intervention.

Documented Manifestations and Severe Outcomes

Overdose manifestations typically begin with gastrointestinal distress, including severe abdominal pain, vomiting (potentially bloody), and bloody diarrhea. As toxicity progresses, systemic effects may include low blood pressure (hypotension), rapid heart rate (tachycardia), lethargy, stupor, seizures, and coma.

Severe Outcomes: A documented risk is the progression to organ damage, including acute liver failure (hepatic necrosis) and shock. Overdose of iron-containing products is specifically noted as a leading cause of fatal poisoning in children under six years of age.

Required Emergency Actions

The most critical action is to seek emergency medical attention immediately following any suspected or accidental ingestion. Official labeling mandates contacting a doctor or a Poison Control Center at once. Hospitalization is required for individuals with high serum iron levels or significant symptoms for continuous monitoring and management.

Management and Antidote

The specific management protocols documented in regulatory sources involve supportive and symptomatic measures, including fluid replacement to manage shock. The chelating agent Deferoxamine is specifically indicated as the antidote for severe systemic iron poisoning. Procedures like whole-bowel irrigation may also be required to remove unabsorbed tablets.

Therapeutic Uses of Feratab

What Feratab Treats: Main Uses and Benefits

Feratab is an antianemic agent generally used to treat and prevent conditions related to low iron in the body, and is primarily relevant in contexts marked by the systemic needs of iron restoration. Its therapeutic benefit is centered on managing the systemic effects of iron depletion, which represents a primary indication for its use.

Therapeutic Domains and Symptom Relief

The medication is commonly used to address conditions such as Iron-Deficiency Anemia (IDA) and earlier states of latent iron deficiency where the condition affects the body's physiological balance. The primary therapeutic use is relevant for easing this condition, which is associated with a physiological iron deficit. This intervention is commonly used across conditions presenting with systemic discomfort or when low iron levels are anticipated due to ongoing chronic issues.

Feratab is applied across domains where additional symptomatic support is appropriate, typically when symptoms cluster into patterns that interfere with daily comfort. It is commonly used to manage symptoms related to extreme fatigue, generalized weakness, and significant lethargy. This usage offers supportive relief which may assist with maintaining a sense of stability when symptoms are more noticeable.

Quick Fact: Symptomatic Relief
Key Use Management of fatigue, weakness, and physical discomfort
Relevant Context Conditions involving episodic or fluctuating manifestations of iron deficiency
Benefit Contributes to improved day-to-day comfort and supports functional stability

Regulatory References

  1. NIH StatPearls on Iron Supplementation

Eligibility and Restrictions for Use

Eligibility and Contraindications

Official regulatory documents define the population eligible to use Feratab (Ferrous Sulfate) based on hematologic status, underlying medical history, and age.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used in the following patient groups, as noted in the product labeling:

  • Patients with Iron Overload Conditions, including hemochromatosis or hemosiderosis.
  • Individuals receiving repeated blood transfusions.
  • Patients with non-iron deficiency anemias, such as hemolytic anemia or pernicious anemia, unless a co-existing iron deficiency is specifically confirmed.
  • Individuals with an active peptic ulcer, ulcerative colitis, or regional enteritis.
  • Patients with known hypersensitivity to ferrous sulfate or any component of the tablet.

Age-Specific Eligibility Rules

Age Group Regulatory Status
Infants / Children under 6 Not Recommended. Absolute warning due to risk of fatal poisoning from accidental overdose.
Children under 12 Not Recommended for tablet forms; consultation is required.
Adults / Adolescents Permitted for the treatment and prevention of diagnosed iron deficiency.
Older Adults (Geriatric) Use with Caution is advised, particularly for those with swallowing difficulties, due to tablet retention risk.

Conditional Use and Status

Use requires caution in patients with a history of peptic ulcer or inflammatory bowel disease. For Pregnancy, use is generally permitted for deficiency treatment and often recommended for prophylaxis during the second and third trimesters. Use is acceptable during Lactation.

What should I know about interactions with other medicines?

Feratab's interaction profile is primarily defined by a pharmacokinetic constraint where it reduces the systemic exposure of several co-administered medicines. This is officially documented as being mediated by the formation of insoluble complexes (cation binding) in the gastrointestinal tract, leading to reduced absorption of the other agent. Medicines officially listed as being affected include Tetracycline and Quinolone antibiotics, the thyroid hormone replacement Levothyroxine, and antiparkinsonian agents such as Levodopa and Methyldopa, along with agents like Penicillamine and Mycophenolate.

To counter this effect, official labeling specifies mandatory time separation rules. For Levothyroxine and Penicillamine, doses must be separated by at least two hours. Tetracycline antibiotics require separation by two or three hours. Additionally, certain combinations are strongly restricted, such as the mandated avoidance of co-administration with Dimercaprol.

Interaction with non-medicinal substances is also documented. Tea, coffee, milk, dairy products, eggs, and whole-grain breads may impair the absorption of iron itself and require a two-hour separation window. Conversely, co-administration with Ascorbic Acid (Vitamin C) is officially noted to increase iron absorption. A specific population note is that alcohol may increase iron absorption and hepatic storage, which is a regulatory consideration for increased toxicity risk in the context of alcoholism.

Mechanism of Action

Feratab, an iron preparation often supplied as ferrous sulfate, exerts its action by engaging several fundamental physiological and cellular pathways to augment the body's available iron pool.


Regulation of Cellular Iron Transport

This domain centers on the processes of iron uptake and systemic distribution. The drug introduces elemental iron (as the divalent cation Fe^2+) into the gastrointestinal tract, where it is internalized by enterocytes via specialized carrier proteins, notably Divalent Metal Transporter 1 (DMT1). This mechanism directly influences the early molecular steps that govern systemic iron balance, affecting the flow of iron into the circulation.


Hemoglobin and Heme Synthesis Support

Following absorption, iron is transported to the bone marrow where it serves as an essential required constituent for the synthesis of heme, a prosthetic group critical to the hemoglobin protein. This supports the entire erythropoietic cascade, resulting in changes to red blood cell parameters and supporting molecular interactions fundamental for oxygen binding.


Activation of Iron-Dependent Enzymes and Proteins

Feratab replenishes the iron pool necessary for various non-hematologic biological processes. This includes acting as a cofactor for enzymes integral to the electron transport chain, intermediary energy metabolism, and nucleotide synthesis. The presence of iron influences the kinetic activity of specific metabolic enzymes, thereby contributing to the modulation of pathway flux.

Dosage and Administration Information

How to Use Feratab: Official Administration Guidelines

Feratab (Ferrous Sulfate) is administered according to established standardized regimens to ensure proper iron replenishment. These instructions define the correct route, dosage, frequency, and administration conditions.

Official Route and Dosing

The only approved route of administration for Feratab tablets is oral (by mouth). Dosing is determined by the specific therapeutic goal, such as treating an iron deficit or preventing one (prophylaxis).

Purpose Standard Adult Dosing (Elemental Iron Equivalent) Frequency
Treatment of Deficiency 65 mg (from 325 mg Ferrous Sulfate) One to three times daily
Prophylaxis/Supplementation 65 mg (from 325 mg Ferrous Sulfate) Once daily

Administration Requirements and Duration

Proper ingestion technique is utilized to help avoid local irritation. Tablets must be swallowed whole with water and should not be chewed, crushed, or sucked. While iron is absorbed best on an empty stomach, the tablet may be taken with or immediately after food to lessen common gastrointestinal discomfort.

Treatment for established iron-deficiency is not short-term; it is a continuous course typically maintained for several months to not only correct the deficiency but also to replenish the body's iron stores. If a dose is missed, it is generally advised to take the next dose at the regular time and not taking a double dose.

Use in Specific Groups

The standard adult tablet strength is not typically recommended for children under 12 years of age due to dosing complexity and safety risks; weight-based dosing with liquid or other pediatric formulations is usually required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Feratab

Research Evidence for Treating Iron-Deficiency Anemia (IDA)

Research has primarily examined the use of Ferrous Sulfate (the active ingredient in Feratab) in short- to intermediate-term Randomized Controlled Trials (RCTs) and subsequent systematic reviews. This research was conducted on populations of adults and children who had been diagnosed with nutritional Iron-Deficiency Anemia. Research examined key blood markers in these populations, such as Hemoglobin (Hb) and Serum Ferritin levels.

These trials report how symptoms evolved in the observed populations. Research highlights changes measured during the study period, where findings describe patterns observed in the studies related to variability in these blood markers over a duration typically ranging from a few weeks to four months. Furthermore, studies examined outcomes related to physical discomfort, such as generalized fatigue and weakness, monitoring whether these symptoms changed over time in the observed populations.

Research Evidence for Preventing Iron Deficiency During Pregnancy

Ferrous sulfate was evaluated in systematic reviews and RCTs that included pregnant women, often comparing it to a placebo or no intervention. These studies focused on outcomes related to systemic or functional imbalance during pregnancy. Researchers examined the incidence of maternal anemia and iron deficiency at the time of delivery. They also monitored fetal outcomes, including measures such as birth weight and the rate of preterm birth.

Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to maternal anemia incidence. Research highlights changes measured during the study period that describe patterns related to infant birth weight, with evidence describing low birth weight occurrence in the observed populations. However, data show patterns related to other clinical outcomes, such as the rate of preterm birth, where findings were mixed and certainty remains low.

What is Still Uncertain About the Research for Feratab

The evidence base, while extensive for acute iron correction, still contains several research limitation frames. Specifically, there is limited information for long-term outcomes, as most studies do not follow patients for a year or longer to assess the sustained impact of the medication. The research highlights what is known and what is still uncertain regarding long-term functional status.

Furthermore, evidence quality varies across studies, leading to uncertainty in specific subgroups. For instance, data for certain groups, such as older adults with complex comorbidities, remain insufficient. The evidence is limited in defining whether an individual's outcomes will align with the group patterns observed in the studies.

Key Studies & References

  1. Iron Supplementation (StatPearls - NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Feratab (FAQ)


Q: How long can I expect to take Feratab?

Official treatment guidelines describe the duration based on the goal of iron restoration. The course described for treating an iron deficiency often involves several months of use. Guidance typically suggests continuing the medicine for 3 to 6 months after the body’s iron levels have returned to normal to help fully replenish internal iron stores.


Q: Are there any long-term side effects associated with Feratab?

Regulatory documents primarily focus on common short-term effects, such as gastrointestinal upset. However, official labeling notes that the medicine is contraindicated (should not be used) in conditions of iron overload, such as hemochromatosis. The potential for this condition is a regulatory consideration associated with prolonged use.


Q: Can I drive or operate machinery while taking Feratab?

Official regulatory information for Feratab does not list side effects that commonly impair a person’s mental or motor function. No general caution regarding the impairment of driving or operating machinery is noted in the official regulatory information.


Q: What do official documents say about the risks of taking Feratab long-term?

The primary regulatory concern documented for prolonged use is the risk of developing iron overload conditions, such as hemochromatosis or hemosiderosis. These conditions are listed as contraindications on official labeling.


Q: Is Feratab a type of antibiotic?

No. Official regulatory documents classify Feratab, which contains ferrous sulfate, as an antianemic agent and an iron preparation. Its documented purpose is to restore the body’s iron levels, not to treat bacterial infections.


Q: What is the difference between Feratab and [Name of a similar drug]?

Feratab contains the active ingredient ferrous sulfate. Official documents describe ferrous sulfate as one of the most readily absorbed iron salts available for oral iron supplementation. Other iron replacement products may contain different forms of iron, such as ferrous fumarate or ferrous gluconate.


Q: How quickly does Feratab start to work?

While iron absorption begins immediately after taking the medicine, measurable changes in blood markers take time to develop. Research findings describe that changes in key blood markers like hemoglobin have been observed within the first two to four weeks of use in observed populations.


Q: Is Feratab available in liquid form for people who can't swallow pills?

Regulatory information confirms that ferrous sulfate, the active ingredient in Feratab, is available in liquid formulations. Liquid preparations are noted as an available formulation option.


Q: What patient population was Feratab originally studied in?

Research has primarily examined the active ingredient, ferrous sulfate, in adult and pediatric populations. These studies focused on individuals who had been diagnosed with nutritional Iron-Deficiency Anemia.


Q: Can I stop taking Feratab suddenly, or do I need to taper off?

Official guidelines define the duration of treatment based on the therapeutic goal of iron restoration. There is no official regulatory instruction requiring a gradual reduction, or tapering, when a patient stops taking the medicine.


Q: What's the relationship between Feratab and kidney function?

Official scientific literature confirms that iron deficiency is a contributing factor to anemia in patients with reduced kidney function, often referred to as Chronic Kidney Disease. Official literature describes how iron supplementation is sometimes employed in this patient population.


Q: Is there a large body of clinical research supporting Feratab's use?

Regulatory reviews and official documents note that the evidence base for the use of ferrous sulfate in the acute correction of iron deficiency is considered extensive.


Q: Is Feratab known to cause headaches?

Headaches are not listed among the most common adverse reactions reported in regulatory documents. The most frequently reported side effects are generally related to the gastrointestinal system, such as constipation or stomach upset.


Q: Does Feratab interact with birth control pills?

The specific interaction of ferrous sulfate with oral contraceptive pills is not explicitly listed in the major drug-drug interaction section of official labeling.


Q: Are there any specific warnings about Feratab for people with heart conditions?

Official eligibility rules restrict use in individuals with anemias not caused by iron deficiency, such as hemolytic anemia. There is no explicit general warning against use solely due to a heart condition.


Q: Is there a maximum time length that Feratab is typically prescribed for?

Official guidelines define the duration by the therapeutic goal rather than a fixed maximum time limit. Treatment typically continues until iron stores are fully replenished, which is often 3 to 6 months after the patient's blood levels have normalized.


Q: Can Feratab be split in half?

Official administration guidelines state that tablets must be swallowed whole with water. The guidelines state the tablet must be swallowed whole, and should not be chewed, crushed, or sucked.


Q: Does the efficacy of Feratab change over time?

Efficacy is assessed by monitoring key blood markers throughout the treatment course. Official research has examined how different dosing frequencies, such as alternate day versus daily, may impact efficacy and the body's absorption kinetics over time.


Q: How is Feratab different from a vitamin or mineral supplement?

Feratab contains ferrous sulfate, which is a specific type of mineral supplement essential for health. Official documents classify it as an antianemic agent and an iron replacement product, vital for the body’s systemic oxygen-carrying capacity.


Q: Will Feratab show up on a drug test?

Feratab contains the inorganic iron salt ferrous sulfate, which is not among the substances typically screened for in standard drug tests.

How should Feratab be stored and disposed of?

Storage Conditions

Feratab (ferrous sulfate tablets) must be stored at 25 C (77 F), which corresponds to controlled room temperature. The official labeling permits temporary temperature excursions between 15 C and 30 C (59 F and 86 F). The product must be stored in a manner that maintains its stability until the labeled expiration date.

Child Safety Warning

The label carries the explicit, mandatory warning to keep this product out of reach of children. Accidental overdose of iron-containing products is cited in regulatory documents as a leading cause of fatal poisoning in children under six.

Disposal Instructions

Official disposal guidance prioritizes taking unused or expired Feratab to a community drug take-back program or utilizing a prepaid mail-back envelope. If no take-back option is available, the tablets should be mixed with an undesirable substance (such as dirt or used coffee grounds), placed in a sealed container, and then discarded in the household trash. The tablets are not on the list of medicines recommended for disposal by flushing down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Feratab found in:

A-Z Index: